Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/123199
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVan Vollenhoven, Ronald F.-
dc.contributor.authorVoskuyl, Alexandre E.-
dc.contributor.authorBertsias, George-
dc.contributor.authorAranow, Cynthia-
dc.contributor.authorAringer, Martin-
dc.contributor.authorArnaud, Laurent-
dc.contributor.authorAskanase, Anca-
dc.contributor.authorBalá ová, Petra-
dc.contributor.authorBonfa, Eloisa-
dc.contributor.authorBootsma, Hendrika-
dc.contributor.authorBoumpas, Dimitrios-
dc.contributor.authorBruce, Ian N.-
dc.contributor.authorCervera i Segura, Ricard, 1960--
dc.contributor.authorClarke, Ann E.-
dc.contributor.authorConey, Cindy-
dc.contributor.authorCostedoat-Chalumeau, Nathalie-
dc.contributor.authorCzirják, László-
dc.contributor.authorDerksen, R. H. W. M.-
dc.contributor.authorDoria, Andrea-
dc.contributor.authorDörner, Thomas-
dc.contributor.authorFischer-Betz, Rebecca-
dc.contributor.authorFritsch-Stork, Ruth-
dc.contributor.authorGordon, Caroline-
dc.contributor.authorGraninger, Winfried-
dc.contributor.authorGyöri, Noémi-
dc.contributor.authorHoussiau, Frédéric A.-
dc.contributor.authorIsenberg, David-
dc.contributor.authorJacobsen, Søren-
dc.contributor.authorJayne, David-
dc.contributor.authorKuhn, Annegret-
dc.contributor.authorLe Guern, Véronique-
dc.contributor.authorLerstrøm, Kirsten-
dc.contributor.authorLevy, Roger A.-
dc.contributor.authorMachado-Ribeiro, Francinne-
dc.contributor.authorMariette, Xavier-
dc.contributor.authorMissaykeh, Jamil-
dc.contributor.authorMorand, Eric-
dc.contributor.authorMosca, Marta-
dc.contributor.authorInanc, Murat-
dc.contributor.authorNavarra, Sandra-
dc.date.accessioned2018-06-22T08:07:58Z-
dc.date.available2018-06-22T08:07:58Z-
dc.date.issued2016-11-24-
dc.identifier.issn0003-4967-
dc.identifier.urihttps://hdl.handle.net/2445/123199-
dc.description.abstractObjectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBMJ Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519-
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561-
dc.relation.urihttps://doi.org/10.1136/annrheumdis-2016-209519-
dc.rights(c) BMJ Publishing Group, 2016-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationLupus eritematós-
dc.subject.classificationMalalties autoimmunitàries-
dc.subject.classificationFarmacologia-
dc.subject.classificationEstudi de casos-
dc.subject.otherLupus erythematosus-
dc.subject.otherAutoimmune diseases-
dc.subject.otherPharmacology-
dc.subject.otherCase studies-
dc.titleA framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec678610-
dc.date.updated2018-06-22T08:07:58Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid27884822-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
678610.pdf533.34 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.